Importantly, this study highlights the emerging role of predictive biomarkers—including tumor mutational burden, interferon signaling defects, CD8+ T cell infiltration, PD-L1 expression, and gut microbiota composition—in influencing response to OV therapy. This evidence concerns the gene CD8A and neoplasm.